Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 Immunogenicity and Safety During Adjuvant Chemotherapy
KCT0003379Phase 3Active, not recruiting
- Sponsor
- Chonnam National University Hwasun Hospital
- Start
- Apr 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Prevnar 13 in pneumococcal disease, sponsored by Chonnam National University Hwasun Hospital. Primary endpoints: Immunogenicity of PCV13 and Safety of PCV13. Started Apr 2016; status: active, not recruiting.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on KCT0003379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003379.